S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   164.05 (-0.50%)
MSFT   278.85 (-0.52%)
META   168.78 (-0.86%)
GOOGL   116.83 (-0.40%)
AMZN   138.23 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.46 (-3.07%)
NIO   20.23 (+0.30%)
BABA   91.03 (+0.21%)
AMD   97.85 (-2.22%)
MU   58.65 (-4.56%)
T   18.04 (+0.22%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.71 (-0.44%)
DIS   109.65 (+0.49%)
AMC   23.55 (-1.71%)
PYPL   95.47 (-0.82%)
PFE   49.48 (-0.18%)
NFLX   231.58 (-0.82%)
S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   164.05 (-0.50%)
MSFT   278.85 (-0.52%)
META   168.78 (-0.86%)
GOOGL   116.83 (-0.40%)
AMZN   138.23 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.46 (-3.07%)
NIO   20.23 (+0.30%)
BABA   91.03 (+0.21%)
AMD   97.85 (-2.22%)
MU   58.65 (-4.56%)
T   18.04 (+0.22%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.71 (-0.44%)
DIS   109.65 (+0.49%)
AMC   23.55 (-1.71%)
PYPL   95.47 (-0.82%)
PFE   49.48 (-0.18%)
NFLX   231.58 (-0.82%)
S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   164.05 (-0.50%)
MSFT   278.85 (-0.52%)
META   168.78 (-0.86%)
GOOGL   116.83 (-0.40%)
AMZN   138.23 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.46 (-3.07%)
NIO   20.23 (+0.30%)
BABA   91.03 (+0.21%)
AMD   97.85 (-2.22%)
MU   58.65 (-4.56%)
T   18.04 (+0.22%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.71 (-0.44%)
DIS   109.65 (+0.49%)
AMC   23.55 (-1.71%)
PYPL   95.47 (-0.82%)
PFE   49.48 (-0.18%)
NFLX   231.58 (-0.82%)
S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   164.05 (-0.50%)
MSFT   278.85 (-0.52%)
META   168.78 (-0.86%)
GOOGL   116.83 (-0.40%)
AMZN   138.23 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.46 (-3.07%)
NIO   20.23 (+0.30%)
BABA   91.03 (+0.21%)
AMD   97.85 (-2.22%)
MU   58.65 (-4.56%)
T   18.04 (+0.22%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.71 (-0.44%)
DIS   109.65 (+0.49%)
AMC   23.55 (-1.71%)
PYPL   95.47 (-0.82%)
PFE   49.48 (-0.18%)
NFLX   231.58 (-0.82%)
NASDAQ:STRO

Sutro Biopharma - STRO Stock Forecast, Price & News

$6.19
+0.43 (+7.47%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.77
$6.41
50-Day Range
$3.41
$6.39
52-Week Range
$3.33
$23.70
Volume
427,771 shs
Average Volume
496,126 shs
Market Capitalization
$290.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.33

Sutro Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
293.1% Upside
$24.33 Price Target
Short Interest
Healthy
12.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.00mentions of Sutro Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.27) to ($3.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

691st out of 1,098 stocks

Biological Products, Except Diagnostic Industry

105th out of 174 stocks

STRO stock logo

About Sutro Biopharma (NASDAQ:STRO) Stock

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Wall Street Analyst Weigh In

STRO has been the topic of several analyst reports. Wedbush lowered their target price on Sutro Biopharma from $30.00 to $20.00 in a research note on Tuesday, May 10th. JMP Securities restated a "buy" rating and issued a $20.00 target price on shares of Sutro Biopharma in a research note on Wednesday, July 6th. HC Wainwright lowered their target price on shares of Sutro Biopharma from $35.00 to $30.00 in a report on Wednesday, May 11th. Finally, Piper Sandler increased their price target on shares of Sutro Biopharma to $16.00 in a report on Monday, July 4th.

Sutro Biopharma Price Performance

Shares of NASDAQ:STRO traded up $0.43 during midday trading on Monday, hitting $6.19. The company had a trading volume of 427,771 shares, compared to its average volume of 738,003. The firm has a market capitalization of $290.52 million, a price-to-earnings ratio of -2.53 and a beta of 0.94. Sutro Biopharma has a twelve month low of $3.33 and a twelve month high of $23.70. The business has a 50-day simple moving average of $5.09 and a two-hundred day simple moving average of $6.84. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 0.06.

Sutro Biopharma (NASDAQ:STRO - Get Rating) last issued its earnings results on Monday, May 9th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by ($0.05). The company had revenue of $5.90 million during the quarter, compared to analysts' expectations of $11.48 million. Sutro Biopharma had a negative net margin of 215.16% and a negative return on equity of 42.97%. Equities research analysts anticipate that Sutro Biopharma will post -3.27 earnings per share for the current year.

Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Stock News Headlines

Short Volatility Alert: Sutro Biopharma, Inc.
See More Headlines
Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Company Calendar

Last Earnings
11/10/2021
Today
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.33
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+293.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-105,540,000.00
Net Margins
-215.16%
Pretax Margin
-215.16%

Debt

Sales & Book Value

Annual Sales
$61.88 million
Book Value
$5.46 per share

Miscellaneous

Free Float
44,540,000
Market Cap
$290.50 million
Optionable
Not Optionable
Beta
0.94

Key Executives

  • Mr. William J. Newell J.D. (Age 64)
    CEO & Director
    Comp: $1.06M
  • Mr. Edward C. Albini (Age 64)
    CFO & Sec.
    Comp: $596.4k
  • Dr. Trevor J. Hallam (Age 63)
    Pres of Research & Chief Scientific Officer
    Comp: $882.83k
  • Dr. Arturo M. Molina FACP (Age 63)
    M.D., M.S., MS, Chief Medical Officer
    Comp: $691.83k
  • Ms. Jane Chung R.Ph. (Age 51)
    Chief Commercial Officer
    Comp: $832.52k
  • Dr. James R. Swartz Ph.D.
    Sc.D., Founder
  • Dr. Shabbir T. Anik (Age 69)
    Chief Technical Operations Officer
  • Ms. Annie J. Chang M.B.A.
    VP of Investor Relations
  • Mr. David Pauling J.D.
    M.A., Gen. Counsel
  • Ms. Linda A. Fitzpatrick (Age 65)
    Chief People & Communications Officer













STRO Stock - Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STRO shares.
View STRO analyst ratings
or view top-rated stocks.

What is Sutro Biopharma's stock price forecast for 2022?

4 equities research analysts have issued 1 year target prices for Sutro Biopharma's stock. Their STRO share price forecasts range from $16.00 to $30.00. On average, they expect the company's share price to reach $24.33 in the next twelve months. This suggests a possible upside of 293.1% from the stock's current price.
View analysts price targets for STRO
or view top-rated stocks among Wall Street analysts.

How has Sutro Biopharma's stock price performed in 2022?

Sutro Biopharma's stock was trading at $14.88 at the start of the year. Since then, STRO stock has decreased by 58.4% and is now trading at $6.19.
View the best growth stocks for 2022 here
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) announced its earnings results on Wednesday, November, 10th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.65) by $0.02. The firm had revenue of $8.52 million for the quarter, compared to analyst estimates of $8.85 million. Sutro Biopharma had a negative net margin of 215.16% and a negative trailing twelve-month return on equity of 42.97%.

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (3.97%), Walleye Capital LLC (0.58%), Russell Investments Group Ltd. (0.28%), Los Angeles Capital Management LLC (0.15%), Candriam S.C.A. (0.13%) and Connor Clark & Lunn Investment Management Ltd. (0.06%). Insiders that own company stock include Arturo Md Molina, John Gordon Freund, Nicki Vasquez, Trevor Hallam and William J Newell.
View institutional ownership trends
.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $6.19.

How much money does Sutro Biopharma make?

Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $290.52 million and generates $61.88 million in revenue each year. The company earns $-105,540,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Sutro Biopharma have?

Sutro Biopharma employs 224 workers across the globe.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The official website for the company is www.sutrobio.com. The company can be reached via phone at (650) 392-8412 or via email at ajchang@sutrobio.com.

This page (NASDAQ:STRO) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.